- Home
- URG vs PHAT Comparison
URG vs PHAT Comparison
Compare URG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- PHAT
- Stock Information
- Founded
- URG 2004
- PHAT 2018
- Country
- URG United States
- PHAT United States
- Employees
- URG N/A
- PHAT N/A
- Industry
- URG Precious Metals
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- URG Basic Materials
- PHAT Health Care
- Exchange
- URG Nasdaq
- PHAT Nasdaq
- Market Cap
- URG 339.5M
- PHAT 289.0M
- IPO Year
- URG N/A
- PHAT 2019
- Fundamental
- Price
- URG $1.06
- PHAT $10.42
- Analyst Decision
- URG Strong Buy
- PHAT Strong Buy
- Analyst Count
- URG 2
- PHAT 5
- Target Price
- URG $2.45
- PHAT $16.40
- AVG Volume (30 Days)
- URG 8.5M
- PHAT 4.7M
- Earning Date
- URG 08-08-2025
- PHAT 08-07-2025
- Dividend Yield
- URG N/A
- PHAT N/A
- EPS Growth
- URG N/A
- PHAT N/A
- EPS
- URG N/A
- PHAT N/A
- Revenue
- URG $33,706,000.00
- PHAT $81,859,000.00
- Revenue This Year
- URG N/A
- PHAT $195.45
- Revenue Next Year
- URG $251.38
- PHAT $106.76
- P/E Ratio
- URG N/A
- PHAT N/A
- Revenue Growth
- URG 200.09
- PHAT 3055.70
- 52 Week Low
- URG $0.55
- PHAT $2.21
- 52 Week High
- URG $1.53
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- URG 65.53
- PHAT 78.59
- Support Level
- URG $0.90
- PHAT $4.47
- Resistance Level
- URG $1.14
- PHAT $11.28
- Average True Range (ATR)
- URG 0.08
- PHAT 1.45
- MACD
- URG 0.02
- PHAT 0.38
- Stochastic Oscillator
- URG 82.48
- PHAT 76.46
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.